Tonix Pharmaceuticals and Tonix Medicines have acquired two migraine products from Upsher-Smith Laboratories.
Approved by the US Food and Drug Administration (FDA), Zembrace SymTouch (sumatriptan injection) 3mg and Tosymra (sumatriptan nasal spray) 10mg are intended to treat adults with acute migraine irrespective of aura status.
The companies entered the acquisition agreement for the products in June 2023.
Zembrace SymTouch is a sumatriptan autoinjector with a low-dose formulation.
It has demonstrated onset of migraine pain relief in around ten minutes, and in a double-blind, single-attack trial, was found to provide 46% of individuals freedom from migraine pain within two hours.
Tosymra has pharmacokinetics in line with a 4mg dose of sumatriptan administered subcutaneously, and leverages an Intravail permeation enhancer technology.
For some individuals, one spray of Tosymra is claimed to provide relief from migraine pain in under ten minutes.
The latest takeover will aid Tonix in bolstering its commercial expertise and infrastructure before the launch of its TNX-102 SL for fibromyalgia.
Tonix Pharmaceuticals CEO Seth Lederman stated: “The acquisition of these two products represents an important step in the evolution of Tonix into a fully integrated biopharmaceutical company and builds on our expertise in central nervous systems disorders.
“In addition to the potential growth that these two on-market products represent over time, the acquisition helps build Tonix’s commercial capabilities ahead of the potential launch of our TNX-102 SL product candidate for the treatment of fibromyalgia, and aligns strongly with our TNX-1900 (intranasal potentiated oxytocin) product candidate in clinical development for the prevention of headaches in chronic migraine.”